Ocular actions of platelet-activating factor: Clinical implications

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 10, 2012, Pages 1027-1039

  Nitoda, Eirini ^a   Moschos, Marilita M ^a   Mavragani, Clio P ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Inflammatory mediators; Ocular inflammation; PAF; PAF antagonists

Indexed keywords

1 0 ALKYL 2 ACETYL SN GLUCERYL 3 PHOSPHORYLCHOLINE; 1 0 ALKYL 2 ACETYL SN GLUCERYL 3 PHOSPHORYLCHOLINE ACETYLHYDROLASE; 1 0 ALKYL 2 ACETYL SN GLUCERYL 3 PHOSPHORYLCHOLINE RECEPTOR; 1 [2 [[5 (N OCTADECYLCARBAMOYLOXYMETHYL)TETRAHYDROFURFURYLOXY]HYDROXYPHOSPHINYLOXY]ETHYL]QUINOLINIUM; 1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID METHYL 2 PHENYLTHIOETHYL ESTER; 2,4,6 TRIMETHYL 1,4 DIHYDRO 3,5 PYRIDINEDICARBOXYLIC ACID 2 (3,4 DICHLOROPHENOXY)ETHYL BIS(MORPHOLINOMETHYL)METHYL ESTER; AGENTS ACTING ON THE EYE; APAFANT; BN 50726; CV 3698; GINKGOLIDE B; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPID; THG 315; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGY; BLOOD RETINA BARRIER; BURN; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG TARGETING; EYE INFLAMMATION; HUMAN; HYPOXIA; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; UVEA; UVEITIS; VISUAL SYSTEM; WOUND HEALING IMPAIRMENT;

ANIMALS; EYE DISEASES; HUMANS; INFLAMMATION; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84866479091     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.712961     Document Type: Review

References (98)

1. Yadav UC, Srivastava SK, Ramana KV. Understanding the role of aldose reductase in ocular inflammation. Curr Mol Med 2010;10:540-9
2. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89-96 (Pubitemid 18057324)
3. Stern ME, Schaumburg CS, Dana R, et al. Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol 2010;3:425-42
4. Berkhoff M, Sturzenegger M, Schroth G, et al. Ocular myositis. Nervenarzt 1997;68:792-800 (Pubitemid 27456467)
5. Irani AM. Ocular mast cells and mediators. Immunol Allergy Clin North Am 2008;28:25-42
6. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol 2008;153:17-21 (Pubitemid 352020378)
7. Ramana KV. Tumor necrosis factor-alpha converting enzyme: implications for ocular inflammatory diseases. Int J Biochem Cell Biol 2010;42:1076-9
8. Malesinski R, Mrugacz M, Bakunowicz-Lazarczyk A. The role of chemokines in ocular diseases. Part II. Participation of chemokines in ocular diseases. Klin Oczna 2007;109:345-8
9. Wallace GR, John Curnow S, Wloka K, et al. The role of chemokines and their receptors in ocular disease. Prog Retin Eye Res 2004;23:435-48 (Pubitemid 38829451)
10. Bhattacherjee P. The role of arachidonate metabolites in ocular inflammation. Prog Clin Biol Res 1989;312:211-27
11. Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine 1992;4:1-5
12. Bora NS, Jha P, Bora PS. The role of complement in ocular pathology. Semin Immunopathol 2008;30:85-95
13. Ianopol N. Free radicals and eye inflammations. Oftalmologia 1998;42:5-9
14. Wakamatsu TH, Dogru M, Tsubota K. Tearful relations: oxidative stress, inflammation and eye diseases. Arq Bras Oftalmol 2008;71:72-9
15. Garweg JG, Candolfi E. Immunopathology in ocular toxoplasmosis: facts and clues. Mem Inst Oswaldo Cruz 2009;104:211-20
16. Yang D, Elner SG, Bian ZM, et al. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 2007;85:462-72 (Pubitemid 47531733)
17. Wakamatsu TH, Dogru M, Ayako I, et al. Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease. Mol Vis 2010;16:2465-75
18. Yadav UC, Kalariya NM, Ramana KV. Emerging role of antioxidants in the protection of uveitis complications. Curr Med Chem 2011;18(6):931-42.
19. Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993;292:617-29 (Pubitemid 23210185)
20. Serhan CN, Haeggstrom JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J 1996;10:1147-58 (Pubitemid 26276957)
21. Derewenda ZS, Derewenda U. The structure and function of platelet-activating factor acetylhydrolases. Cell Mol Life Sci 1998;54:446-55 (Pubitemid 28260596)
22. Stafforini DM, McIntyre TM, Zimmerman GA, et al. Platelet-activating factor acetylhydrolases. J Biol Chem 1997;272:17895-8 (Pubitemid 27306362)
23. Arai H. Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat 2002;68-69:83-94 (Pubitemid 35247389)
24. Sweeney KJ, Clark GD, Prokscha A, et al. Lissencephaly associated mutations suggest a requirement for the PAFAH1B heterotrimeric complex in brain development. Mech Dev 2000;92:263-71 (Pubitemid 30155920)
25. Adachi H, Tsujimoto M, Hattori M, et al. Differential tissue distribution of the beta-and gamma-subunits of human cytosolic platelet-activating factor acetylhydrolase isoform I. Biochem Biophys Res Commun 1997;233:10-13 (Pubitemid 27215899)
26. Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J 1992;6:2296-301
27. McManus LM, Pinckard RN. PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med 2000;11:240-58 (Pubitemid 30481383)
28. Bhatia M. Inflammatory response on the pancreatic acinar cell injury. Scand J Surg 2005;94:97-102 (Pubitemid 41169982)
29. Neoptolemos JP, Raraty M, Finch M, et al. Acute pancreatitis: the substantial human and financial costs. Gut 1998;42:886-91 (Pubitemid 28277235)
30. Chen C, Xia SH, Chen H, et al. Therapy for acute pancreatitis with platelet-activating factor receptor antagonists. World J Gastroenterol 2008;14:4735-8
31. Kitagawa D, Taketomi A, Kayashima H, et al. Expression of platelet-activating factor receptor: a novel prognosticator in patients with hepatocellular carcinoma following hepatectomy. Oncology 2007;72:381-7 (Pubitemid 351238153)
32. Reynaud S, Malissein E, Donnard M, et al. Functional platelet-activating factor receptors in immature forms of leukemic blasts. Leuk Res 2007;31:399-402 (Pubitemid 46073171)
33. Denizot Y, Donnard M, Guglielmi L, et al. Detection of functional platelet-activating factor receptors on leukemic B cells of chronic lymphocytic leukemic patients. Leuk Lymphoma 2004;45:515-18 (Pubitemid 38196034)
34. Fernandes CJ, O'Donovan DJ. Platelet transfusions in infants with necrotizing enterocolitis. Curr Hematol Rep 2006;5:76-81
35. Edwards LJ, Constantinescu CS. Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases. Inflamm Allergy Drug Targets 2009;8:182-90
36. Wierzbicki M, Brzezinska-BLaszczyk E. The role of mast cells in the development of inflammatory bowel diseases. 2008;62:642-50
37. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001;15:2073-2084 (Pubitemid 32927925)
38. Noto H, Hara M, Karasawa K, et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23:829-35 (Pubitemid 36566173)
39. Zhou G, Marathe GK, Willard B, et al. Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. J Biol Chem 2011;286:34820-9
40. Ho YS, Swenson L, Derewenda U, et al. Brain acetylhydrolase that inactivates platelet-activating factor is a Gprotein-like trimer. Nature 1997;385:89-93 (Pubitemid 27024561)
41. Umemura K, Kato I, Hirashima Y, et al. Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia. Stroke 2007;38:1063-8 (Pubitemid 46568475)
42. Marques M, Pei Y, Southall MD, et al. Identification of platelet-activating factor acetylhydrolase II in human skin. J Invest Dermatol 2002;119:913-19 (Pubitemid 35340918)
43. Sreevidya CS, Fukunaga A, Khaskhely NM, et al. Agents that reverse UV-Induced immune suppression and photocarcinogenesis affect DNA repair. J Invest Dermatol 2010;30:1428-37
44. Rosenbaum JT, Boney RS, Samples JR, et al. Synthesis of platelet activating factor by ocular tissue from inflamed eyes. Arch Ophthalmol 1991;109:410-13
45. Pisella PJ. Pathology of the ocular surface. Rev Prat 2006;56:1226-31
46. Calonge M, Enriquez-de-Salamanca A, Diebold Y, et al. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm 2010;18:244-53
47. Sharif NA, Xu S, Hellberg PE, et al. Human conjunctival epithelial cell responses to platelet-activating factor (PAF): signal transduction and release of proinflammatory cytokines. Mol Vis 2009;15:1153-61
48. Okumura N, Fukushima A, Igarashi A, et al. Pharmacokinetic analysis of platelet-activating factor in the tears of guinea pigs with allergic conjunctivitis. J Ocul Pharmacol Ther 2006;22:347-52 (Pubitemid 44706527)
49. Zinchuk O, Fukushima A, Zinchuk V, et al. Direct action of platelet activating factor (PAF) induces eosinophil accumulation and enhances expression of PAF receptors in conjunctivitis. Mol Vis 2005;11:114-23 (Pubitemid 41358301)
50. Kato M, Imoto K, Miyake H, et al. Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs. J Pharmacol Sci 2004;95:435-42 (Pubitemid 39237472)
51. Kato M, Kurose T, Oda T, et al. The role of platelet activating factor and the efficacy of apafant ophthalmic solution in experimental allergic conjunctivitis. J Ocul Pharmacol Ther 2003;19:315-24 (Pubitemid 37013005)
52. Thakur A, Willcox MD, Stapleton F. The proinflammatory cytokines and arachidonic acid metabolites in human overnight tears: homeostatic mechanisms. J Clin Immunol 1998;18:61-70 (Pubitemid 28079074)
53. Thakur A, Willcox MD. Cytokine and lipid inflammatory mediator profile of human tears during contact lens associated inflammatory diseases. Exp Eye Res 1998;67:9-19 (Pubitemid 28364810)
54. Ma X, Bazan HE. Increased platelet-activating factor receptor gene expression by corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2000;4:1696-702 (Pubitemid 30354339)
55. Chandrasekher G, Ma X, Lallier TE, et al. Delay of corneal epithelial wound healing and induction of keratocyte apoptosis by platelet-activating factor. Invest Ophthalmol Vis Sci 2002;43:1422-8 (Pubitemid 34462640)
56. Kenchegowda S, Bazan HE. Significance of lipid mediators in corneal injury and repair. J Lipid Res 2010;51:879-91
57. Bazan H, Ottino P. The role of platelet-activating factor in the corneal response to injury. Prog Retin Eye Res 2002;21:449-64 (Pubitemid 35245966)
58. Ottino P, He J, Axelrad TW, et al. PAF-induced furin and MT1-MMP expression is independent of MMP-2 activation in corneal myofibroblasts. Invest Ophthalmol Vis Sci 2005;46:487-96 (Pubitemid 40270326)
59. Bazan HE. Cellular and molecular events in corneal wound healing: significance of lipid signalling. Exp Eye Res 2005;80:453-63 (Pubitemid 40387514)
60. Taheri F, Bazan HE. Platelet-activating factor overturns the transcriptional repressor disposition of Sp1 in the expression of MMP-9 in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2007;48:1931-41 (Pubitemid 351261257)
61. He J, Bazan HE. Synergistic effect of platelet-activating factor and tumor necrosis factor-alpha on corneal myofibroblast apoptosis. Invest Ophthalmol Vis Sci 2006;47:883-91 (Pubitemid 46768318)
62. Esquenazi S, Bazan HE. Role of platelet-activating factor in cell death signaling in the cornea: a review. Mol Neurobiol 2010;42:32-8
63. Esquenazi S, He J, Bazan HE, et al. Prevention of experimental diffuse lamellar keratitis using a novel platelet-activating factor receptor antagonist. J Cataract Refract Surg 2004;30:884-91 (Pubitemid 38501486)
64. Esquenazi S, He J, Li N, et al. A novel platelet activating factor receptor antagonist reduces cell infiltration and expression of inflammatory mediators in mice exposed to desiccating conditions after PRK. Clin Dev Immunol 2009;2009:138513
65. He J, Bazan NG, Bazan HE. Alkali-induced corneal stromal melting prevention by a novel platelet-activating factor receptor antagonist. Arch Ophthalmol 2006;124:70-8 (Pubitemid 43063891)
66. Ma X, Ottino P, Bazan HE, Bazan NG. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Invest Ophthalmol Vis Sci 2004;45:2915-21 (Pubitemid 39121817)
67. He J, Eastlack JP, Bazan HE. The induction of an angiogenic response in corneal myofibroblasts by platelet-activating factor (PAF). Curr Eye Res 2010;35:1063-71
68. Spalton DJ, Hitchings RA, Hunter PA. Clinical anatomy of the eye. Times Mirror International Publishers Ltd; London, 1998
69. Sohn JH, Bora PS, Jha P, et al. Complement, innate immunity and ocular disease. Chem Immunol Allergy 2007;92:105-14 (Pubitemid 47096900)
70. Garland RC, Sun D, Zandi S, et al. Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury. FASEB J 2011;25:1284-94
71. Tunc SE, Aksu K, Keser G, et al. Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behcet's patients. Rheumatol Int 2005;25:326-31 (Pubitemid 40922247)
72. Fleisher LN, Ferrell JB, Smith MG, et al. Lipid mediators of tumor necrosis factor-alpha-induced uveitis. Invest Ophthalmol Vis Sci 1991;32:2393-9
73. Yousufzai SY, Abdel-Latif AA. Effects of platelet-activating factor on the release of arachidonic acid and prostaglandins by rabbit iris smooth muscle. Inhibition by calcium channel antagonists. Biochem J 1985;228(3):697-706 (Pubitemid 15011521)
74. Tsuji F, Shirasawa E. The role of platelet-activating factor in cell infiltration in endotoxin-induced uveitis in guinea pigs. Curr Eye Res 1998;17:501-5 (Pubitemid 28306505)
75. Lin N, Bazan HE, Braquet P, et al. Prolonged effect of a new platelet-activating factor antagonist on ocular vascular permeability in an endotoxin model of uveitis. Curr Eye Res 1991;10(1):19-24
76. Rosenbaum JT, Angell E, Wilson D, et al. Intravitreally injected platelet activating factor induces retinitis in experimental animals. Curr Eye Res 1999;18:342-8 (Pubitemid 29237876)
77. Crane IJ, Liversidge J. Mechanisms of leukocyte migration across the blood-retina barrier. Semin Immunopathol 2008;30:165-77
78. Cheng L, Han X, Shi Y. A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice. Am J Physiol Endocrinol Metab 2009;297:E1276-82
79. Hardy P, Beauchamp M, Sennlaub F, et al. New insights into the retinal circulation: inflammatory lipid mediators in ischemic retinopathy. Prostaglandins Leukot Essent Fatty Acids 2005;72:301-25 (Pubitemid 40590052)
80. Beauchamp MH, Marrache AM, Hou X, et al. Platelet-activating factor in vasoobliteration of oxygen-induce retinopathy. Invest Ophthalmol Vis Sci 2002;43:3327-37
81. Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 2005;32:89-103 (Pubitemid 41113211)
82. de la Cruz JP, Moreno A, Ruiz-Ruiz MI, et al. Effect of WEB 2086-BS, an antagonist of platelet-activating factor receptors, on retinal vascularity in diabetic rats. Eur J Pharmacol 1998;360:37-42 (Pubitemid 28529394)
83. Smith D, Lee EK, Saloupis P, et al. Role of neutrophils in breakdown of the blood-retinal barrier following intravitreal injection of platelet-activating factor. Exp Eye Res 1994;59:425-32 (Pubitemid 24352076)
84. Dharma S, Bazan HE, Peyman GA, Atef MS. Production of platelet-activating factor in photocoagulated retinas. Curr Eye Res 1991;10:1031-5
85. Menerath JM, Cluzel J, Droy-Lefaix MT, et al. Experimental electroretinographic exploration of retinal ischemia: preventive use of free radical scavengers and anti-PAF agents. J Ocul Pharmacol Ther 1997;13:81-8 (Pubitemid 27130724)
86. He YG, Wang H, Zhao B, et al. Functional analysis of platelet-activating factor in the retinal pigment epithelial cells and choroidal endothelial cells. Curr Eye Res 2009;34:957-65
87. Vinores SA, Xiao WH, Shen J, et al. TNF-alpha is critical for ischemia induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol 2007;182:73-9 (Pubitemid 46039759)
88. Cluzel J, Doly M, Bazan NG, et al. Inhibition of platelet-activating factorinduced retinal impairments by cholera and pertussis toxins. Ophthalmic Res 1995;27:153-7
89. Doly M, Braquet P, Bonhomme B, et al. Effects of PAF-acether on electrophysiological response of isolated retina. Int J Tissue React 1987;9:33-7 (Pubitemid 17063229)
90. Thierry A, Doly M, Braquet P, et al. Presence of specific platelet-activating factor binding sites in the rat retina. Eur J Pharmacol 1989;163:97-101 (Pubitemid 19107547)
91. Meyniel G, Doly M, Millerin M, et al. Involvement of PAF (Platelet-Activating Factor) in chloroquine-induced retinopathy. C R Acad Sci III 1992;314:61-5
92. Doly M, Cluzel J, Millerin M, et al. Prevention of chloroquine-induced electroretinographic damage by a new platelet-activating factor antagonist, BN 50730. Ophthalmic Res 1993;25:314-18 (Pubitemid 23310512)
93. Droy-Lefaix MT, Vennat JC, Besse G, et al. Effect of Gingko biloba extract (EGb 761) on chloroquine induced retinal alterations. Lens Eye Toxic Res 1992;9:521-8 (Pubitemid 23111722)
94. Doly M, Millerin M, Bonhomme B, et al. Inhibition of vincristine-induced retinal impairments by a specific PAF antagonist. Lens Eye Toxic Res 1992;9:529-35 (Pubitemid 23111723)
95. Reme C, Wei Q, Munz K, et al. Light and lithium effects in the rat retina: modification by the PAF antagonist BN 52021. Graefes Arch Clin Exp Ophthalmol 1992;230:580-8
96. Bussolino F, Torelli S, Stefanini E, et al. Platelet-activating factor production occurs through stimulation of cholinergic and dopaminergic receptors in the chick retina. J Lipid Mediat 1989;1:283-8 (Pubitemid 19278283)
97. Bussolino F, Pescarmona G, Camussi G, et al. Acetylcholine and dopamine promote the production of platelet activating factor in immature cells of chick embryonic retina. J Neurochem 1988;51:1755-9 (Pubitemid 19010961)
98. Fragel-Madeira L, Meletti T, Mariante RM, et al. Platelet activating factor blocks interkinetic nuclear migration in retinal progenitors through an arrest of the cell cycle at the S/G2 transition. PLoS One 2011;6:e16058